Please login to the form below
inflammatory conditions
This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.
Roche’s COVID-19 antibody receives FDA approval for hospitalised adults
indicated for a variety of other inflammatory conditions over the years.
Latest news
-
Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
The drug has already been on the US market for more than two decades for the treatment of rheumatoid arthritis, and has been indicated for a variety of other inflammatory conditions ... as well as a variety of inflammatory conditions.
-
AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
This latest agreement is the second between the two companies and expands on the first multi-target discovery deal signed in June 2020, which focuses on autoimmune and inflammatory disease areas. ... According to the conditions of the new agreement,
-
Almirall and Evotec team up in multi-target dermatology alliance
The multi-target research and development partnership will focus on severe, chronic skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal
-
AbbVie’s Crohn’s disease drug given green light by MHRA
She added: “Working with the MHRA to bring risankizumab to eligible people with Crohn’s disease reflects our ambition to bring innovative medicines to people with debilitating conditions like inflammatory bowel
-
Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
Atopic dermatitis is one of the most common inflammatory skin conditions – affecting around 5-10% of adults living in the US, while 1 in 3 suffer with moderate-to-severe symptoms – ... Mike Gladstone, global president of Pfizer Inflammation
More from news
Approximately 0 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
However, we must not neglect the fact that, for non-COVID patients, many people have faced delays and cancellations for the treatment of debilitating conditions, such as Inflammatory Bowel Disease (IBD) ... With a focus on inflammatory and fibrotic
-
Drug launches to watch in 2019
conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... Boehringer Ingelheim) for psoriatic
-
Medius Deal Watch table for April 2015
49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.
-
Pharma deals in April 2015
Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),
-
Deal Watch table for April 2014
7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
In this role, Genovese will oversee the clinical development of Gilead’s investigational portfolio of treatments for inflammatory conditions.
-
Sanofi’s US pharma head joins Synta as CEO
She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.
-
Novo's Wagtmann joins Innate as chief scientific officer
research into immunotherapies for cancer and inflammatory diseases. ... He is familiar with Innate through its collaboration with Novo on immunotherapies, including IPH2201, a monoclonal antibody targeting NKG2A in development to treat patients with
-
Former Sanofi SVP to chair Idera
Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion ... conditions. 19th July 2013.
-
AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO
and autoimmune conditions. ... multiple sclerosis and secukinumab for several inflammatory conditions.
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Fishawack Health welcomes expert-led dermatology initiative FIDE to its group
November 10, 2021, UK.Fishawack Health, the leading commercialization partner for the life science industry, welcomes FIDE to its group—an independent expert-led consultancy specializing in chronic inflammatory skin conditions ... Fishawack Health’s
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
